Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.


TSXV:TELO - Post by User

Telo Genomics Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by westdakotadaveon Mar 17, 2023 2:12pm
158 Views
Post# 35345552

$TDSGF GAMEPLAN

$TDSGF GAMEPLAN
$TDSGF GAMEPLAN per Feb 28, 2023 Filing (SEDAR MD&A)
 
March 2023 = Mayo SMM results have been submitted to the American Society of Clinical Oncology (ASCO) for presentation.
June 2023 = ISO 15189 approval that allows Telo to issue laboratory developed tests ("LDT") commercially.
June 2-6, 2023 = Telo at ASCO booth IH18.
June 2023 = Mayo SMM results to be submitted/published to a op-tier hematology journal (Probably the Blood Journal).
July 2023 = Launch of TeloView-MM laboratory developed tests ("LDT").
September 2023 = Anticipated Mayo results for testing to Predict Patient Resistance to Treatment.
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities